Increased circulating regulatory T cells in medicated people with schizophrenia.

Psychiatry Res

Laboratory of Behavioral Neuroimmunology, Department of Psychiatry, University of Maryland School of Medicine, 685 West Baltimore Street, MSTF Building Room 934 E, Baltimore 21201, MD, USA. Electronic address:

Published: November 2018

AI Article Synopsis

  • Researchers have noted immunological abnormalities in schizophrenia, but specific biomarkers linked to its genetics are still unclear.
  • The study examined Treg (regulatory T cells) levels in 26 schizophrenia patients and 17 healthy controls, finding significantly more Tregs in patients.
  • Higher Treg levels were associated with fewer negative symptoms, suggesting that Tregs might help alleviate these symptoms by reducing inflammation in schizophrenia.

Article Abstract

Immunological abnormalities are increasingly reported in people with schizophrenia, but no clear functional biomarkers associated with genetic correlates of the disease have been found. Regulatory T cells (Tregs) are key immunoregulatory cells involved in the control of inflammatory processes and their functions are directly related to the human leucocyte antigen (HLA) gene, which has been implicated in schizophrenia genetic studies. However, there is a lack of studies reporting Treg status in people with schizophrenia. In the current study, the proportion of circulating Tregs was examined using flow cytometry in 26 medicated participants with schizophrenia and 17 healthy controls. Psychiatric symptoms and cognitive function were evaluated using the Scale for the Assessment of Negative Symptoms, the Brief Psychiatric Rating Scale, and the MATRICS Consensus Cognitive Battery. The proportion of Tregs was found to be significantly greater in the schizophrenia group compared to healthy controls. No differences were observed in total lymphocyte counts or CD3 and CD4 T cells, confirming a specific effect for Tregs. Elevated Tregs in schizophrenia correlated with fewer negative symptoms, a core domain of the illness. These results suggest that Tregs may contribute to improved negative symptoms in schizophrenia, possibly by counteracting on-going inflammatory processes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207456PMC
http://dx.doi.org/10.1016/j.psychres.2018.09.006DOI Listing

Publication Analysis

Top Keywords

people schizophrenia
12
negative symptoms
12
regulatory cells
8
schizophrenia
8
inflammatory processes
8
healthy controls
8
tregs
6
increased circulating
4
circulating regulatory
4
cells
4

Similar Publications

Background: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition emerging in early childhood, characterized by core features such as sociocommunicative deficits and repetitive, rigid behaviors, interests, and activities. In addition to these, disruptive behaviors (DB), including aggression, self-injury, and severe tantrums, are frequently observed in pediatric patients with ASD. The atypical antipsychotics risperidone and aripiprazole, currently the only Food and Drug Administration-approved treatments for severe DB in patients with ASD, often encounter therapeutic failure or intolerance.

View Article and Find Full Text PDF

Aim: To investigate the detection and initial management of first psychotic episodes, as well as established schizophrenia, within the primary care of the Andalusian Health System.

Background: Delay in detecting and treating psychosis is associated with slower recovery, higher relapse risk, and poorer long-term outcomes. Often, psychotic episodes go unnoticed for years before a diagnosis is established.

View Article and Find Full Text PDF

Purpose: We aimed to verify the impact of functional remediation (FR) on serum brain-derived neurotrophic factor (BDNF) and tyrosine kinase receptor B (TrkB) levels, to explore the biomechanism of FR intervention in patients with euthymic bipolar disorder (BD).

Patients And Methods: This is a randomized controlled, 12-week intervention study with participants randomized into the FR group (n=39) and the treatment as usual group (TAU, n=42) at the 1∶1 ratio. 17-Hamilton Depression Rating Scale-17 (HDRS-17), Young Mania Rating Scale (YMRS), and Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) were used to assess affective symptoms and cognitive functioning both at baseline and week 12, respectively.

View Article and Find Full Text PDF

Rising studies have consistently reported gut bacteriome alterations in schizophrenia (SCZ). However, little is known about the role of the gut virome on shaping the gut bacteriome in SCZ. Here in, we sequenced the fecal virome, bacteriome, and host peripheral metabolome in 49 SCZ patients and 49 health controls (HCs).

View Article and Find Full Text PDF

Background: Estimating the prevalence of schizophrenia in the general population remains a challenge worldwide, as well as in Japan. Few studies have estimated schizophrenia prevalence in the Japanese population and have often relied on reports from hospitals and self-reported physician diagnoses or typical schizophrenia symptoms. These approaches are likely to underestimate the true prevalence owing to stigma, poor insight, or lack of access to health care among respondents.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!